I-Corps: Early Preeclampsia Detection Strip (EPED)

I-Corps项目更广泛的影响/商业潜力是通过改变医疗保健的访问方式来改变医疗保健的进程。早期子痫前期检测（ped）条提供无创，快速，点护理诊断子痫前期（PE），在妊娠早期。早期PE检测可以保证更安全的妊娠。即使在没有表现症状的情况下，ped也可以帮助临床医生轻松地识别PE，并且没有识别白大褂综合征的挑战。准妈妈们可以控制自己的健康，在家里快速舒适地进行测试。等待检查结果是有压力的，对许多女性来说，去诊所预约会带来巨大的负担。ped为更好、更快、更多地获得医疗保健提供了答案。提高个人对并发症发生的认识，并向妇女提供控制自身健康所需的工具，对于减轻先兆子痫和子痫的负担，并使成千上万的母亲和婴儿免受可预防的伤害至关重要。这个I-Corps项目旨在探索先兆子痫诊断的需求及其设计规范。这一信息的发现将有助于开发一种基于尿液的即时检测测试，该测试使用侧流技术来测量蛋白质生物标志物的升高水平，这是先兆子痫的指示。研究小组已经确定了两种与子痫前期和子痫相关的生物标志物，这在文献和我们的临床工作中得到了证明。当发现高于阈值浓度时，生物标志物将确认先兆子痫的发展。为了检测这些生物标志物，该团队选择使用横向流动分析格式，因为它易于使用和高效的设计。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is to change the course of healthcare by changing how it is accessed. The Early Preeclampsia Detection (EPED) Strip provides non-invasive, rapid, point-of-care diagnosis of preeclampsia (PE), early in pregnancy. Early PE detection allows for a safer pregnancy. EPED can aid clinicians to identify PE with ease, even when there are no presenting symptoms, and without the challenge of discerning white coat syndrome. Expecting mothers can take control of their health and test quickly and comfortably at home. Awaiting test results is stressful, and for many women, getting to a clinical appointment poses a huge burden. EPED provides answers for better, faster, and increased access to healthcare. Increasing individual awareness about developing complications and providing women with the tools they need to take control of their own health is essential to reducing the burden of preeclampsia and eclampsia, and saving thousands of mothers and babies from preventable harm.This I-Corps project aims to explore the need for a preeclampsia diagnostic as well as its design specifications. Discovery of this information will allow for the development of a urine-based, point-of-care detection test that uses lateral flow technology to measure elevated levels of protein biomarkers, which are indicative of preeclampsia. The team has identified two biomarkers of interest which are associated with preeclampsia and eclampsia, as evidenced in literature and in our clinical work. When found above threshold concentration, the biomarkers will confirm the development of preeclampsia. To detect these biomarkers, the team has chosen to use a lateral flow assay format because of its ease of use and efficient design.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.